Loading…
TRIMETHOPRIM is a brand name for Trimethoprim. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Trimethoprim is indicated for the prevention and treatment of urinary tract infections in adults and children, and the treatment of other susceptible infections in adults and children caused by a wide range of trimethoprim sensitive Gm +ve and Gm -ve organisms including Haemophilus influenzae, Streptococcus…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults & Children over 12 years of age Treatment of urinary tract infections and all other susceptible infections: 200 mg (20 ml) twice daily. Long-term prevention of recurrent urinary tract infections: 100 mg (10 ml) at night.
Children 6 weeks to 12 years of age Treatment of urinary tract infections is based on a dosage of 8 mg/kg body weight daily, subdivided into two equal doses. 5 ml) twice daily 6 months - 5 years - 50 mg (5 ml) twice daily 6 years - 12 years - 100 mg (10 ml) twice daily Long-term prevention of recurrent urinary tract infection is based on 2 mg/kg body weight daily given as a single dose at night.
5 ml) at night 6 years - 12 years - 50 mg (5 ml) at night Dosage advised where there is reduced kidney function: eGFR (ml/min) Dosage advised Over 30 Normal 15- 30 Normal for 3 days then half dose Under 15 Half the normal dose Monitoring of renal function and serum electrolytes should be considered particularly with longer term use, in patients with impaired renal function.
Trimethoprim should only be initiated and used in dialysis patients under close supervision from specialists in both infectious disease and renal medicine. Trimethoprim is removed by dialysis. Monitoring trimethoprim plasma concentration may be considered with long term therapy but the value of this in individual cases should first be discussed with specialists in infectious disease and renal medicine.
Elderly Depending on kidney function, see special dosage schedule. Method of administration For oral administration
The following list of undesirable effects have been reported by healthcare professionals. Sometimes it may be difficult to distinguish reactions caused by the condition being treated from adverse drug reactions, which means that not all the listed reactions were caused by drug administration.
Infections and Infestations Common:
Monilial overgrowth Blood and lymphatic system disorders Very rare: Leucopenia, neutropenia, thrombocytopenia, pancytopaenia, bone marrow depression, agranulocytosis, aplastic anaemia, haemolytic anaemia, eosinophilia, purpura, haemolysis.
Not known:
Megaloblastic anaemia, methaemoglobinaemia, depression of haematopoiesis. 3 Contraindications), however the majority of haematological changes are mild and reversible when treatment is stopped.
Immune system disorders Very rare:
Hypersensitivity, anaphylaxis, angioedema, drug fever, allergic vasculitis resembling Henoch-Schoenlein purpura, periarteritis nodosa, systemic lupus arythematosus.
Metabolism and nutrition disorders Very common:
Hyperkalaemia Very rare: Hypoglycaemia, hyponatraemia, anorexia. Close supervision is recommended when trimethoprim is used in elderly patients or in patients taking high doses as these patients may be more susceptible to hyperkalaemia and hyponatraemia.
Psychiatric disorders Very rare:
Depression, hallucinations, confusional states, agitation, anxiety, abnormal behaviour, insomnia and nightmares.
Nervous system disorders Common:
1. 3 PHARMACEUTICAL FORM Oral suspension. White opaque smooth suspension. coli, Enterobacter, Proteus and Streptococcus faecalis. 2 Posology and method of administration Posology Adults & Children over 12 years of age Treatment of urinary tract infections and all other susceptible infections: 200 mg (20 ml) twice daily.
Long-term prevention of recurrent urinary tract infections: 100 mg (10 ml) at night. Children 6 weeks to 12 years of age Treatment of urinary tract infections is based on a dosage of 8 mg/kg body weight daily, subdivided into two equal doses.
5 ml) twice daily 6 months - 5 years - 50 mg (5 ml) twice daily 6 years - 12 years - 100 mg (10 ml) twice daily Long-term prevention of recurrent urinary tract infection is based on 2 mg/kg body weight daily given as a single dose at night.
5 ml) at night 6 years - 12 years - 50 mg (5 ml) at night Dosage advised where there is reduced kidney function: eGFR (ml/min) Dosage advised Over 30 Normal 15- 30 Normal for 3 days then half dose Under 15 Half the normal dose Monitoring of renal function and serum electrolytes should be considered particularly with longer term use, in patients with impaired renal function.
Trimethoprim should only be initiated and used in dialysis patients under close supervision from specialists in both infectious disease and renal medicine. Trimethoprim is removed by dialysis. Monitoring trimethoprim plasma concentration may be considered with long term therapy but the value of this in individual cases should first be discussed with specialists in infectious disease and renal medicine.
Elderly Depending on kidney function, see special dosage schedule. 1. Trimethoprim is contra-indicated in severe hepatic insufficiency. Trimethoprim is contra-indicated in megaloblastic anaemia and other blood dyscrasias. 6), premature infants or children under 4 months.
4 Special warnings and precautions for use Care is necessary in administration to patients with impaired renal function. Regular haematological tests should be performed during long term therapy. In patients with renal impairment, care should be taken to avoid accumulation.
1. Trimethoprim is contra-indicated in severe hepatic insufficiency. Trimethoprim is contra-indicated in megaloblastic anaemia and other blood dyscrasias. 6), premature infants or children under 4 months.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Trimethoprim in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Headache Very rare: Dyskinesias, aseptic meningitis, tremor, ataxia, dizziness, lethargy, syncope, paraesthesiae, convulsions, peripheral neuritis, vertigo, tinnitus. Aseptic meningitis was rapidly reversible on withdrawal of the drug, but recurred in a number of cases on re-exposure to either co-trimoxazole or to trimethoprim alone.
Eye disorders Very rare: uveitis.
Respiratory, thoracic and mediastinal disorders Very rare:
Cough, shortness of breath, wheeze, epistaxis.
Gastrointestinal disorders Common:
Nausea, diarrhoea, vomiting.
Very rare:
Constipation, glossitis, stomatitis, pseudomembranous colitis, pancreatitis.
Unknown:
Sore mouth, gastro-intestinal disturbance Hepatobiliary disorders Very rare: Elevation of serum transaminases, elevation of bilirubin levels, cholestatic jaundice, hepatic necrosis. Cholestatic jaundice and hepatic necrosis may be fatal.
Skin and subcutaneous tissue disorders Common:
Skin rashes, urticaria Very rare: Photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, erythema nodusum, Stevens-Johnson Syndrome, toxic epidermal necrolysis, bullous dermatitis, purpura.
Not known:
Pruritus, Drug reaction with eosinophilia and systemic symptoms (DRESS). Lyell's syndrome (toxic epidermal necrolysis) carries a high mortality.
Musculoskeletal and connective tissue disorders Very rare:
Arthralgia, myalgia and uveitis.
Renal and urinary disorders Very rare:
Impaired renal function (sometimes reported as renal failure), haematuria. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Monitoring of renal function and serum electrolytes should be considered particularly with longer term use. Trimethoprim should only be initiated and used in dialysis patients under close supervision from specialists in both infectious disease and renal medicine.
Trimethoprim may cause depression of haemopoiesis. g. the elderly), to check for possible pancytopaenia. If there is evidence of folic acid deficiency, calcium folinate should be administered and response checked by haematologic monitoring.
It may be necessary to discontinue trimethoprim. Particular care should be exercised in the haematological monitoring of children on long term therapy. Isolated cases of megaloblastic anaemia during prolonged therapy with trimethoprim in doses higher than those recommended have been reported but these are reversible with discontinuation of therapy and administration of calcium folinate.
If a patient has a known or suspected risk of acute prophyria, treatment with trimethoprim should be avoided. 8). Elevations in serum potassium have been observed in some patients treated with trimethoprim. g. heparin). 5). 5). 8). Patients should be advised of the signs and symptoms and monitored closely for skin reactions.
If signs and symptoms suggestive of these reactions appear, trimethoprim should be withdrawn immediately and an alternative treatment considered (as appropriate). If the patient has developed a serious reaction such as SJS, TEN or DRESS with the use of trimethoprim, the treatment must not be restarted in this patient at any time.
Trimethoprim Oral Suspension contains sodium methyl parahydroxybenzoate (E219) and sodium propyl parahydroxybenzoate (E217). These may cause allergic reactions (possibly delayed). It also contains maltitol liquid. Patients with rare hereditary problems of fructose intolerance […]